Why the study?
Does Troponin I evaluation identify trastuzumab-treated patients at risk for cardiotoxicity and lack of recovery from cardiac dysfunction?
Does Troponin I evaluation identify trastuzumab-treated patients at risk for cardiotoxicity and lack of recovery from cardiac dysfunction?
Answers are grounded in this paper and cite their sources.
Troponin I positivity identifies trastuzumab-treated patients at high risk for irreversible cardiotoxicity, highlighting its prognostic value in cardio-oncology.
TNI+ identifies trastuzumab-treated patients who are at risk for cardiotoxicity and are unlikely to recover from cardiac dysfunction despite HF therapy.
No takes yet. Share an insight, caveat, or question.
Cardinale et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: